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Statement of findings
We tested the hypothesis that BRCA1 may play a role in the regulation of ovarian tumor cell
death as well as the inhibition of ovarian cell proliferation. Introduction of BRCA1 antisense
retroviral constructs into BG-1 estrogen-dependent ovarian adenocarcinoma cells resulted
in reduced BRCA1 expression. BRCA1 antisense pooled populations and derived
subclones were able to proliferate in monolayer culture without estrogen, whereas control
cells began to die after 10 days of estrogen deprivation. In addition, both populations and
subclones of BRCA1 antisense infected cells demonstrated a growth advantage in
monolayer culture in the presence of estrogen and were able to proliferate in monolayre
culture without estrogen, while control cells did not. Furthermore, clonal studies
demonstrated that reduced levels of BRCA1 protein correlated with growth in soft agar and
greater tumor formation in nude mice in the absence of estrogen. These data suggest that
reduction of BRCA1 protein in BG-1 ovarian adenocarcinoma cells may have an effect on
cell survival during estrogen deprivation both in vitro and in vivo.
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Introduction: Germline mutations in the breast and ovarian
cancer susceptibility gene BRCA1, which is located on
chromosome 17q21, are associated with a predisposition to
the development of cancer in these organs [1,2]. No mutations
in the BRCA1 gene have been detected in sporadic breast
cancer cases, but mutations have been detected in sporadic
cases of ovarian cancer [3,4]. Although there is debate
regarding the level of cancer risk associated with mutations in
BRCA1 and the significance of the lack of mutations in
sporadic tumors, it is possible that alterations in the function of
BRCA1 may occur by mechanisms other than mutation,
leading to an underestimation of risk when it is calculated
solely on the basis of mutational analysis. Such alterations
cannot be identified until the function and regulation of BRCA1
are better understood.
The BRCA1 gene encodes a 220-kDa nuclear phosphoprotein
that is regulated in response to DNA damaging agents [5–7]
and in response to estrogen-induced growth [8–11]. Germline
mutations that cause breast and ovarian cancer predisposition
frequently result in truncated and presumably inactive BRCA1
protein [12].
BG-1 cells were derived from a patient with stage III, poorly
differentiated ovarian adenocarcinoma [13]. This cell line,
which expresses wild-type BRCA1, is estrogen responsive and
withdrawal of estrogen results in eventual cell death. Previous
studies suggest that BRCA1 is stimulated as a result of
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estrogen treatment [8–11], and also that BRCA1 may be
involved in the cell death process [14]. Therefore, we examined
the effect of reduction of BRCA1 levels in BG-1 cells on the
cellular response to hormone depletion as well as estrogen
stimulation. The results suggest that reduced levels of BRCA1
correlates with a survival advantage when BG-1 cells are
placed under growth-restrictive and hormone-depleted
conditions. In optimum growth conditions, significantly reduced
levels of BRCA1 correlates with enhanced growth both in vitro
and in vivo.
Aims: To test the hypothesis that BRCA1 may play a role in the
regulation of ovarian tumor cell death as well as in the inhibition
of ovarian cell proliferation.
Materials and methods: The estrogen receptor-positive, BG-1
cell line [13], which contains an abundant amount of estrogen
receptors (600fmoles/100mg DNA), was infected using a
pLXSN retroviral vector (provided by AD Miller) containing an
inverted partial human cDNA 900-base-pair sequence of
BRCA1 (from nucleotide 121 in exon 1 to nucleotide 1025 in
exon 11, accession #U14680). After 2 weeks of selection in
800mg/ml of geneticin-G418 (Gibco/Life Technologies,
Gaithersburg, MD, USA), BG-1 G418-resistant colonies were
pooled, or individually isolated, and assayed for growth in the
presence or absence of supplemented estrogen. Virally infected
pooled populations of BG-1 cells were examined for BRCA1
message levels by ribonuclease protection assay (Fig. 1a).
BRCA1 ribonuclease protection probe was made using an in
vitro transcription kit (Ambion, Inc, Austin, TX, USA) as
previously described [10] and derived clones were tested for
protein levels by Western blot analysis using an anti-BRCA1
(Oncogene Research, Ab-1, Cambridge, MA, USA) antibody.
Growth curve analysis of Infected populations and were
pretreated for 5 days in phenol red-free, Dulbecco’s modified
eagle medium (DMEM)/F-12 medium (Gibco/Life Technologies)
supplemented with 10% charcoal/dextran treated serum
(Hyclone, Logan, UT, USA), then plated at 2.5×106 cells per
100mm dish in triplicate in the absence or presence of
estrogen (10–8mol/l; 17b-Estradiol; 1,3,5 (10) - Estratriene 3,
17b-diol; Sigma, St Louis, MO, USA). For soft agar assay,
clones were plated into 10 60-mm dishes at 1×105 cells/dish
containing 0.3% bactopeptone agar with or without added
estrogen (10–8mol/l) in phenol red-free medium with 10%
stripped serum in order to test for anchorage independent
growth. BG-1 infected clones were tested for tumorigenicity by
injection of cells (106 cells in 0.1cm2 50% matrigel;
Collaborative Biomedical Products, Bedford, MA, USA) into
subcutaneous sites in 6-week-old athymic Ncr-nude mice (NCI
Animal Program, Bethesda, MD, USA) that were ovariectomized
at approximately 4 weeks of age. Half of the ovariectomized
mice received an implanted 0.18mg estrogen 60-day pellet
(Innovative Research of America, Sarasota, FL, USA).
Results: Antisense technology was effective in decreasing
both RNA and protein levels of BRCA1 in the BG-1 human
ovarian adenocarcinoma cells. BRCA1 antisense-infected
populations contained significantly less BRCA1 message than
control LXSN-infected pools and selected clones contained
varying reduced levels of BRCA1 protein compared with
control clones (Figs 1a and 1b).
Three independent BRCA1 antisense-infected cultures
demonstrated a resistance to cell death induced by withdrawal
from estrogen over a 6- to 20-day period (Fig. 2a). The BRCA1
antisense population also exhibited a threefold to sixfold
increase in cell growth compared with control cells in the
presence of estrogen treatment. BG-1 BRCA1 antisense
Figure 1
Expression of BRCA1 is reduced in BG-1 cells following infection with antisense BRCA1. (A) Ribonuclease protection analysis of BRCA1 mRNA.
Lanes 1 and 2 show undigested probe for BRCA1 and loading control, cyclophilin. Lanes 3 and 4 are pooled BG-1 neo-infected control cells
grown minus [Dulbecco’s modified eagle medium (DMEM)] and plus (E2) 10–8mol/l estrogen for 24 h. Lanes 5 and 6 are pooled BG-1 BRCA1
antisense-infected cells minus and plus 10–8mol/l estrogen, respectively, for 24h. The observed doublet is the result of incomplete digestion.
(B) Western blot analysis of individual control (NEO) and BRCA1 antisense (AS) clones. MDAMB468 is a BRCA1-positive breast cancer cell line.
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Figure 2
The effect of estrogen deprivation and estrogen treatment on the growth
of BRCA1 antisense and control cells. (A) The mean cell number of
BRCA1 pooled population antisense infected cells (d) and vector-only
infected cells (s) deprived of estrogen for up to 20 days after plating
2.5×10 6 cells per 100-mm dish. Cells received a pretreatment of 5 days
of estrogen deprivation before plating. (B) The percentage decrease or
fold increase of BG-1 antisense (AS) or NEO clones and parental cells
plated at 106 cells per 60-mm dish after deprivation of estrogen (solid bars) or treatment with 10–8mol/l estrogen (spotted bars) for 8 days.
Percentage decrease or fold increase was calculated on the basis of the change in cell number between days 5 and 8 after treatment or
nontreatment with 10–8mol/l estrogen. Cells were pretreated with 5 days of estrogen deprivation before plating.
clones demonstrated a similar response to pooled population
studies, enhanced growth with estrogen, and failure to die
upon estrogen depletion (Fig. 2b).
The BRCA1 antisense clones were further examined for other
associated tumorigenic properties. All of the antisense clones
were able to form colonies in soft agar (2–23 colonies per 104
cells plated; data not shown), whereas control clones were
deficient in their ability to form colonies (0–0.8 colonies per
104 cells plated). Table 1 shows, in the presence of estrogen,
the clone with the lowest levels of BRCA1 (AS-4) produced
significantly more colonies (133±17.9 colonies per 104 cells
plated) than the control clone (NEO; 6±3.1 colonies per 104
cells plated). Clones AS-4 and NEO were also injected with
matrigel subcutaneously into ovariectomized athymic mice.
Almost twice as many sites were positive for the AS-4 clone
(14 out of 14) as for the NEO clone (eight out of 14) 42 days
after injection. In addition, BRCA1 antisense tumors averaged
twice the size of control tumors. The BRCA1 reduced cells
also formed tumors with half the latency of control cells in the
presence of implanted estrogen (11 days versus 21 days until
tumor formation).
Discussion: The present studies show that reduction in
BRCA1 levels, using an antisense retroviral vector in the
estrogen dependent BG-1 ovarian carcinoma cell line,
contributes to confirmation of the hypothesis that BRCA1 plays
a pivotal role in the balance between cell death and cell
proliferation.  BRCA1 RNA and protein levels were successfully
reduced in populations and isolated clones of antisense
infected BG-1 cells. Decreased BRCA1 levels rescued the
BG-1 cells from growth arrest or cell death in adverse growth
conditions in monolayer or soft agar conditions. Furthermore, a
BRCA1 antisense clone that had significantly low levels of
BRCA1 protein was able to form twice as many tumors in
ovariectomized nude mice with a decreased latency compared
with a control clone.
In multicellular mammalian organisms, a balance between cell
proliferation and cell death is extremely important for the
maintenance of normal healthy tissues. In support of this
hypothesis, it has been shown that p53 and BRCA1 can form
stable complexes, and can coactivate p21 and bax genes,
which may lead to the activation of the apoptosis pathway [15].
The present data, which show that cells with a reduction of
BRCA1 have a survival advantage in conditions where control
Table 1
Number of colonies per 104 cells in agar
– Estrogen + Estrogen
Colonies CFE Colonies CFE
in on in on
Clone Agara Plasticb Agara Plasticb
NEO 0.0±0.0 21 6.0±3.1 19
AS-4 10.0±2.9* 38 133.0±17.9* 39
aMean agar colonies±STD; b% colony forming efficiency on plastic.
*P<0.01 versus Neo 1; n = 5.
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Germline mutations in the breast and ovarian cancer sus-
ceptibility gene BRCA1, which is located on chromosome
17q21, are associated with a predisposition to the devel-
opment of cancer in these organs [1,2]. Initial analyses
[22] suggested that women with germline mutations in the
BRCA1 gene and a strong family history of breast or
ovarian cancer have 85 and 44% lifetime risks of develop-
ing breast and ovarian cancer, respectively. Recent
studies [23], however, have suggested that analyses
based on women who were not selected for a familial
history of cancer indicate that the risk for cancer associ-
ated with mutations in these genes is 50 and 16% for
breast and ovarian cancers, respectively. No mutations in
the BRCA1 gene have been detected in sporadic breast
cancer cases; however, mutations have been detected in
sporadic cases of ovarian cancer [3,4]. Although there is
debate regarding the level of cancer risk associated with
mutations in BRCA1 and the significance of the lack of
mutations in sporadic tumors, it is possible that alterations
in the function of BRCA1 may occur by mechanisms other
than mutation. This would lead to an underestimation of
risk when it is calculated solely on the basis of mutational
analysis. Such alterations cannot be identified until the
function and regulation of BRCA1 are better understood.
The BRCA1 gene encodes a 220-kDa nuclear protein that
may be regulated by phosphorylation through the cell
cycle and in response to DNA damaging agents [5–7].
The level of BRCA1 is also regulated in response to estro-
gen or estrogen-induced growth in breast [8–11] and
ovarian cell lines. BRCA1 has been shown to colocalize in
nuclear dots with other cellular proteins, including
BARD-1 [24], Rad51, PCNA, and BRCA2 [7,25]. In addi-
tion, BRCA1 can act as a transcriptional transactivator in
yeast reporter assays [26,27] and binds the RNA poly-
merase II holoenzyme, a component of the basal transcrip-
tion machinery [25]. The precise mechanism of action and
the specific signaling pathway affected by BRCA1 remain
unknown, however.
Studies of BRCA1 expression patterns in mouse tissue
reveal that BRCA1 is most highly expressed in tissues
undergoing rapid proliferation and differentiation, and that
expression  in vivo is also hormone responsive. For
example, analyses of mammary gland growth and develop-
ment show high levels of BRCA1 expression in terminal
end buds during puberty and in budding alveoli during
pregnancy. In addition, hormonal stimulation in ovariec-
tomized mice results in induction of BRCA1 expression in
the breast [28]. Attempts to develop homozygous,
BRCA1-deleted mouse models have resulted in embry-
onic lethality [29,30]. For example, when the BRCA1 gene
deletion was targeted in exons 5 and 6, mutant mice died
before day 7.5 of embryogenesis. Analysis of DNA synthe-
sis in the mutant embryos indicated that cell proliferation
was impaired, suggesting that BRCA1 may paradoxically
play a positive role in the regulation of embryonic cell
growth [29].
Most of the mechanistic BRCA1 studies to date have
been conducted in breast carcinoma cell lines; therefore,
we decided to conduct a study to determine the effect of
BRCA1 expression on the cellular phenotype of an ovarian
carcinoma cell line, BG-1. BG-1 cells were derived from a
patient with stage III, poorly differentiated ovarian adeno-
carcinoma [13]. This cell line, which expresses wild-type
BRCA1, is estrogen responsive, and withdrawal of estro-
gen results in eventual cell death. Previous studies sug-
gested that BRCA1 is stimulated as a result of estrogen
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cells fail to thrive, also supports this hypothesis. BRCA1 levels
appear to affect the ability of cells to arrest growth or die in the
absence of estrogenic growth-inducing conditions. Although
mutations in this gene are uncommon in sporadic breast and
ovarian tumors, BRCA1 expression levels and protein levels
have been found to be reduced in sporadic human breast
carcinomas [16–19]. In addition it has been demonstrated [20]
that hormone-dependent tumors such as breast and ovarian
cancers have a decreased ability to undergo apoptosis. Other
mechanisms involving gene regulation may allow for decreased
expression of BRCA1 in sporadic tumors. The response of
BRCA1  mRNA and protein levels to mitogens and hormones in
vitro suggests that BRCA1 may play a role in regulation of cell
growth or maintenance [21]. The BRCA1 gene product may be
involved in the regulation of hormone response pathways, and
the present results demonstrate that loss of BRCA1 may result
in loss of inhibitory control of these mitogenic pathways. These
studies show that reduction in BRCA1 mRNA and protein can
result in increased proliferation of BG-1 ovarian cancer cells in
both in vitro and in vivo conditions, suggesting that BRCA1
may normally be acting as a growth inhibitor. Low BRCA1
levels found in sporadic cancers may be an important factor in
tumorigenesis. The present data suggest that diminished levels
of BRCA1 not only accelerate proliferation in the BG-1 ovarian
carcinoma cell line, but also appear to promote tumorigenesis.
We propose that the loss or reduction of BRCA1 may
predispose a cell population to neoplastic transformation by
altering the balance between cell death and
proliferation/survival, rendering it more sensitive to secondary
genetic changes.treatment [8–11], and that BRCA1 may be involved in the
cell death process [14]. Therefore, we examined the effect
of reduction of BRCA1 levels in BG-1 cells on the cellular
response to estrogen stimulation as well as hormone
depletion. Our results suggest that when BG-1 cells are
subjected to growth restrictive and hormone-depleted
conditions, cells that have even moderately reduced levels
of BRCA1 protein have a distinct advantage for survival. In
addition, significant reduction in BRCA1 protein level cor-
relates with enhanced estrogen proliferation when com-
pared with cells that express moderate to wild-type
BRCA1 levels, grown under optimal growth conditions
both  in vitro and in vivo.
Materials and methods
Cells and cell culture
The estrogen receptor-positive, BG-1 line [13], which
contains an abundant amount of estrogen receptors
(600fmol/100mg DNA), was provided by J Boyd (Sloan-
Kettering Cancer Center, New York, NY, USA). GPE86
and PA317 viral packaging cell lines were provided by AD
Miller (Fred Hutchinson Cancer Center, Seattle, WA,
USA). BG-1 cells were maintained in Dulbecco’s modified
eagle medium (DMEM)/F12 medium supplemented with
10% fetal calf serum (Summit, Fort Collins, CO, USA),
and 50 units/ml penicillin/streptomycin. BG-1 cells arrest
to gamma radiation consistent with a wildtype p53 pheno-
type. These cells were tested negative for mycoplasmas.
Retroviral vector preparation and infection of cells
A partial human cDNA sequence of BRCA1 (from
nucleotide 121 in exon 1 to nucleotide 1025 in exon 11,
accession #U14680) was inserted in the antisense orien-
tation into the EcoR1 site of the pLXSN retroviral vector
(provided by AD Miller). The vector alone, or the antisense
BRCA1 vector, was transfected using the calcium-phos-
phate precipitation method into the ecotropic packaging
cell line GPE86 [31]. Supernatant, generated from trans-
fected GPE86 cells [31], was then used to infect the
amphotropic packaging cell line PA317 [31] in the pres-
ence of 4 mg/ml polybrene (Abbott Laboratories, Abbott
Park, IL, USA). PA317-infected cells were grown in selec-
tion media for 2 weeks and pooled for supernatant collec-
tion. Supernatants were filtered (0.20mm filter) and tested
for virus-producing cells. Titer efficiencies of the LXSN
virus ranged from 104 to 105 colony-forming units/ml on
mouse cells (A9). Log phase BG-1 cells were exposed to
supernatant containing either the LXSN control retrovirus
or retroviruses containing the antisense BRCA1 cDNA
sequence. After 2 weeks of selection in 800mg/ml of
geneticin-G418 (Gibco/Life Technologies, Gaithersburg,
MD, USA), BG-1 G418-resistant colonies were pooled or
individually isolated and assayed for growth in the pres-
ence or absence of supplemented estrogen. Only isolated
clones were used in anchorage dependence and tumori-
genicity studies.
BRCA1 ribonuclease protection assay and protein analysis
A BRCA1 ribonuclease protection probe was made using
an In Vitro Transcription Kit (Ambion, Inc, Austin, TX, USA).
The DNA template spanned part of exon 22, all of exon 23,
and part of exon 24 of the BRCA1 gene. Template DNA
was incubated for 45 min at 37°C with (a-32P)-uridine
triphosphate and T7 polymerase in the presence of buffer
and nucleotides. DNA template was removed by ribonucle-
ase-free deoxyribonuclease incubation at 37°C for 30 min.
The reaction was stopped by the addition of 0.5mol/l ethyl-
enediaminetetra-acetic acid, and the labeled probe was
purified on a 5% polyacrylamide gel. Sample RNA (20mg
total RNA) was coprecipitated with the BRCA1 probe and
the cyclophilin control probe [32], resuspended in Hyb-
speed RPA (Ambion) hybridization buffer at 95°C, and then
incubated at 68°C for 10 min. Ribonuclease was added
and the sample was incubated for 45 min at 37°C. Pro-
tected fragments were precipitated, and resuspended in
loading buffer, followed by separation on a 5% polyacry-
lamide–urea gel, and exposed to X-ray film.
BRCA1 protein was analyzed by Western blot analysis.
Whole cell lysate (50mg) was loaded onto a 6% sodium
dodecyl sulfate–polyacrylamide gel electrophoresis gel,
transferred to nitrocellulose, and hybridized with an anti-
BRCA1 (Ab-1; Oncogene Research, Cambridge, MA,
USA) antibody as previously described [10].
Estrogen treatment and growth curve analysis
G418-resistant colonies from BRCA1 antisense infected
BG-1 cells and control vector LXSN-infected BG-1 cells
were pooled, pretreated for 5 days in phenol red-free,
DMEM/F-12 medium (Gibco/Life Technologies) supple-
mented with 10% charcoal/dextran treated serum
(Hyclone, Logan, UT, USA), then plated at 2.5×106 cells
per 100mm dish in triplicate for growth curve analysis in
the absence or presence of estrogen (10–8mol/l; 17b-
Estradiol; 1,3,5 (10) - Estratriene 3, 17b-diol; Sigma, St
Louis, MO, USA). Extended growth curve analysis was
plated at 2.5×106 in 100mm dishes for an extended
treatment of 20 days without estrogen. Clones were iso-
lated from the BRCA1 antisense and LXSN BG-1 pooled
populations and grown in phenol red-free, DMEM/F-12
medium (Gibco/Life Technologies) supplemented with
charcoal/dextran treated serum (Hyclone) for 5 days
before plating for growth curve analysis. Cells were then
plated in triplicate at 1×106 cells per 60mm dish in either
the absence or presence of estrogen (10–8mol/l) and
grown for 8–10 days. Cell number was calculated on indi-
cated days using a Coulter counter. The number of dead
cells for the extended growth curve experiment was calcu-
lated by counting trypan blue incorporated cells using a
hemocytometer. Statistical analyses of P values were cal-
culated based on the fold differences between growth of
the clones by computing a mean ratio and the correspond-
ing standard deviation [33].
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Selected BG-1 clones were tested for anchorage inde-
pendent growth in 0.3% bacto-peptone agar with a 0.6%
bacto-peptone agar base plus or minus added estrogen
(10–8mol/l) in phenol red-free medium with 10% stripped
serum. Each BG-1, neomycin-resistant clone was plated
into 10 60-mm dishes containing the agar at 1×105 cells
per dish. Colonies (greater than 30 cells) were scored
after 14 days. Pairwise comparisons were made by a two-
sided Mann–Whitney U test to calculate P values [34].
BG-1-infected clones were tested for tumorigenicity in 6-
week-old athymic Ncr-nude mice (NCI Animal Program,
Bethesda, MD, USA) that were ovariectomized at approxi-
mately 4 weeks of age. BRCA1 antisense clone (AS-4)
was injected (106 cells in 0.1cm2 50% matrigel; Collabora-
tive Biomedical Products, Bedford, MA, USA) into two sub-
cutaneous sites on one side of 16 mice (32 injection sites),
whereas a LXSN control clone was injected on the oppo-
site side of the same mice. Nine of the 16 ovariectomized
mice also received an implanted 0.18mg estrogen 60-day
pellet (Innovative Research of America, Sarasota, FL,
USA). Mice were periodically examined and tumor size was
measured during the 3-month period after injection.
Results
Effective decrease in BRCA1 expression using antisense
technology
Antisense technology was effective in decreasing both
RNA and protein levels of BRCA1 in the BG-1 human
ovarian adenocarcinoma cells. BG-1 human ovarian ade-
nocarcinoma cells were infected with a retroviral construct
composed of an antisense 900 base-pair cDNA sequence
of the amino-terminal region of BRCA1. Three experi-
ments (two of which were from independently made
supernatants) showed that infection of pLXSN (vector
alone) and BRCA1 antisense retroviral constructs into
BG-1 cells yielded G418-resistant colonies at similar rates
(titers ranged from 0.78 to 4.2×104 colony-forming
units/ml). The same vectors were also directly transfected
into BG-1 cells at an efficiency of 6.3×10–5 for the anti-
sense  BRCA1 or 9.9×10–5 for the control plasmid
(pLXSN). Neomycin-resistant colonies were pooled and
examined for BRCA1 message levels by ribonuclease pro-
tection assay. BRCA1 antisense infected cells contained
significantly less BRCA1 message than control LXSN
infected cells, whether cultured in the presence or
absence of estrogen (Fig. 1a). Although there appears to
be no detectable amounts of BRCA1 RNA present after
estrogen withdrawal, low levels of protein can be detected
by western blot analysis [10].
Subclones were also isolated from BRCA1 antisense
infected cells, or LXSN infected cells (NEO). Western blot
analysis demonstrated that all of the antisense BRCA1
clones had reduced levels of BRCA1 protein compared
with the NEO clones, and one antisense clone (AS-4) had
very low levels of BRCA1 protein, although it was not
totally absent (Fig. 1b).
Effects of reduced BRCA1 expression on in vitro growth
Pooled populations of antisense BRCA1 BG-1 colonies
were examined for growth in the absence or presence of
supplemented estrogen. Three independently infected cul-
tures of BRCA1 antisense cells demonstrated a resis-
tance to cell death induced by withdrawal from estrogen
over a 6-day period, as well as a threefold to sixfold
increase in cell growth compared with control cells in the
presence of estrogen treatment (Fig. 3). In order to investi-
gate further whether reduction of BRCA1 protein had an
effect on hormone-dependent cell growth, BG-1 antisense
and control cells were grown in estrogen-deprived condi-
tions for an extended period of time. During the first 5
days, both groups continued to proliferate in the absence
of estrogen, but the BRCA1 antisense group continued to
grow for the next 10 days, whereas control cells
decreased in number (Fig. 2a).
In order to avoid the problem of a mixed population of cells
expressing various levels of BRCA1, subclones were iso-
lated from infected populations of BRCA1 antisense
infected BG-1 cells and control LXSN infected BG-1 cells
(NEO). Figure 2b shows BG-1 parental and NEO clones
exhibited up to a 37% decrease in cell number during a 3-
day period of estrogen withdrawal, whereas antisense
BRCA1 clones showed as much as a twofold increase in
cell number during the same time period. In an attempt to
determine if increased survival of the antisense cells was do
to increased proliferation of the antisense cells or decreased
death rate, the number of trypan blue positive, non-viable
were examined after 14 days without estrogen. There were
5–10-fold more dead cells present in the media of control
cells (BG-1 parental and NEO clone) then in the BRCA1
antisense clone AS-4 (data not shown). It appeared that
resistance to cell death plays a significant role in the survival
of BRCA1 antisense cells to estrogen withdrawal. Figure 2b
again demonstrates the ability of the BRCA1 antisense sub-
clones to survive estrogen deprivation. In the presence of
estrogen, three out of the four antisense BRCA1 clones
exhibited a growth advantage over NEO clones or the BG-1
parental population (Fig. 2b). Antisense BRCA1 clones 1, 3
and 4 showed a 10-fold to 16-fold increase in cell number
between days 5 and 8 after estrogen treatment compared
with only a threefold to fivefold increase of cell number in
NEO clones and BG-1 parental cells (Fig. 2b). The AS-4
clone, which had the lowest levels of BRCA1 protein,
showed a highly significant (16-fold; P<0.01) stimulation of
growth between days 5 and 8 of estrogen induction (Figs 2b
and 4). In summary, although three out of four of the anti-
sense BRCA1 clones had a growth advantage in the pres-
ence of estrogen, all four antisense BRCA1 clones showed
enhanced survival in estrogen-depleted media.
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Anchorage independent growth is a common property of
many transformed cells. Therefore, the BRCA1 antisense
subclones were also studied for anchorage independent
growth in a semisoft agar medium with and without sup-
plemented estrogen. Table 1 shows that colony formation
efficiencies on plastic of control (NEO) and BRCA1 anti-
sense (AS-4) cells were similar in estrogen-depleted and
estrogen-containing media. However, the BG-1 control
clone (NEO) was unable to form colonies (fewer than one
colony per 104 cells plated) in agar without the addition of
estrogen, whereas the BG-1 antisense BRCA1 clone was
able to form soft agar colonies in estrogen depleted condi-
tions (10±2.9 colonies per 104 cells plated). In the pres-
ence of estrogen, both NEO and AS-4 were able to form
colonies; however, there was a significant difference
(P<0.01) in the ability to form colonies in agar between
AS-4 (133 colonies) and the control clone (six colonies).
These data suggest a correlation between the loss of
BRCA1 protein and an increased survival/growth advan-
tage in anchorage-independent conditions.
Effects of reduced BRCA1 protein on in vivo tumor cell
growth
Because the AS-4 clone showed a growth advantage in
soft agar, a phenotype that may be correlated with the
ability to form tumors in vivo, the BRCA1 antisense sub-
clone AS-4 was evaluated for its ability to form subcuta-
neous tumors in ovariectomized athymic mice in the
presence or absence of an estrogen pellet. Mice were
injected subcutaneously with AS-4 cells in matrigel on one
side of each mouse and NEO cells in matrigel on the other
side. Of the mice injected, 50% received an implanted
estrogen pellet (0.18mg estrogen) that was designed to
release estrogen for 60 days. In the absence of estrogen,
a significant difference was detected in tumorigenic
growth between AS-4 and NEO cells (Fig. 5b). Almost
twice as many sites were tumor positive for the AS-4
clones than for NEO injected sites. 100% (14/14) Tumor
formation was reached for all AS-4 clones 42 days after
injection, compared with 57% (eight out of 14) positive
tumor formation of the NEO sites (Fig. 5b, upper panel).
AS-4 cells also formed tumors that averaged twice the
size of NEO control tumors (Fig. 5b, lower panel).
BG-1 cells without matrigel were nontumorigenic in
athymic male or female mice (0 positive sites/20 sites
injected at 5×106 cells per site), but these cells formed
large, progressively growing tumors when injected with
matrigel in the presence of estrogen (Fig. 5a). These
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Figure 3
The growth curve of BG-1 populations infected with BRCA1 antisense
treated with estrogen (10–8mol/l; d) or without estrogen (s); and the
growth curve of BG-1 pooled population infected with pLXSN control
vector treated with estrogen (j) or without estrogen (u) over a 6-day
period. Cells were deprived of estrogen for 5 days before plating
2.5×10 6 cells per 100-mm dish and treatment with estrogen. The
results shown indicate the mean cell number of three pooled
populations after replating.
Figure 4
Estrogen dependent BG-1 cells infected with BRCA1 antisense
continue to proliferate in the absence of estrogen. (A) BG-1 NEO
control subclone on day 14 of estrogen deprivation. (B) BG-1 NEO at
day 9 of 10–8mol/l estrogen treatment. (C) BG-1 BRCA1 antisense
AS-4 subclone on day 14 of estrogen deprivation. (D) BG-1 BRCA1
antisense infected cells at day 9 of 10–8mol/l estrogen treatment.tumors were very large (>1cm diameter) and did not
regress even though the estrogen pellet was effective for
only 60 days (Fig. 5a, lower panel). Similar to the agar
experiments, both the BRCA1 antisense clone and LXSN
control clone were positive for tumor formation in the pres-
ence of estrogen. AS-4 cells formed tumors with half of
the latency of control cells in the presence of implanted
estrogen (Fig. 5a, upper panel; 11 days versus 21 days
until tumor formation). Neither AS-4 nor NEO cells formed
progressively growing tumors in the absence of estrogen,
however. All tumors in the mice without estrogen pellets
had started to regress by 71 days after injection. The
observed tumor regression was not surprising, because
matrigel is not stable for longer than 14 days in culture,
and probably not in vivo either (personal communication;
Collaborative Biomedical Products, Bedford, MA, USA).
By day 71, the matrigel would no longer confer an optimal
growth environment for BG-1 cells.
Discussion
The present studies show that reduction of BRCA1 levels,
using an antisense retroviral vector in the estrogen depen-
dent BG-1 ovarian carcinoma cell line, may aid in confir-
mation of the hypothesis that BRCA1 functions as a tumor
suppressor gene by playing a pivotal role in the balance
between cell death and cell proliferation. BRCA1 RNA
and protein levels were successfully reduced in pooled
and isolated subclones of antisense-infected populations
of BG-1 cells. Decreased BRCA1 levels appeared to
affect the ability of BG-1 cells to arrest growth or die in
the absence of estrogenic growth-inducing conditions.
We found that BRCA1 antisense cells, both as pooled
populations and individual subclones, also exhibited
enhanced growth in monolayer culture on plastic in the
presence of estrogen compared with control vector-
infected colonies. All BRCA1 antisense subclones were
able to proliferate as well as exhibit a decreased death
rate in estrogen-deprived media, whereas parental and
control subclones failed to grow. Death after estrogen
withdrawal has been shown in previous studies using
BG-1 cells [13,35]. BRCA1 antisense subclones demon-
strated other traits associated with a tumorigenic pheno-
type, such as the ability to grow in soft agar independent
of estrogen, whereas control clones could only form
colonies with the addition of estrogen. In ovariectomized
nude mice, a BRCA1 antisense clone (AS-4) was exam-
ined for tumorigenicity compared with a control clone
(NEO). The AS-4 clone formed a greater number of and
larger tumors than NEO in the absence of estrogen, and in
general formed tumors faster in the presence of estrogen.
The main conclusion from these studies is that BG-1
clones with reduced levels of BRCA1 protein have a sur-
vival advantage over controls in the absence of estrogen
both in vitro and in vivo.
The response of BRCA1 mRNA and protein levels to mito-
gens and hormones in vitro suggests that BRCA1 may
play a role in regulation of cell growth or maintenance
[21]. During estrous, many hormones and growth factors
interact in a complex manner as survival factors and induc-
ers of cell proliferation, which are then balanced with
growth inhibitors [36–40]. The mechanism by which
BRCA1 can regulate or influence these processes has not
yet been identified. It has been shown that BRCA1 is
induced as a result of the mitogenic activity of the estro-
gen receptor in estrogen receptor-positive cells [9,10].
Direct estrogen stimulation is not required for BRCA1
transcription, however [9,41]. In support of this, BRCA1
expression has been shown to occur in the mouse ovary
(granulosa and thecal cells of small and medium follicles)
independent of hormonal status, and even in ovaries from
estrogen receptor –/– deficient mice [41,42]. In contrast,
the tumors from patients with BRCA1 mutations appear to
have downregulation of estrogen receptors [43–45]. Pre-
vious experiments in our laboratory showed that another
hormone, progesterone, could also cause a modest
increase of BRCA1 mRNA in BG-1 cells after 24h expo-
sure without an increase in growth (unpublished data).
Progesterone has been found [46] to inhibit cell prolifera-
tion and induce apoptosis significantly in two ovarian car-
cinoma cell lines. Thus, although BRCA1 may not be
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Figure 5
The effect of reduced BRCA1 protein in BG-1 cells on incidence and
size of tumor formation in ovariectomized nude mice. (A) BG-1 BRCA1
antisense clone AS-4 (solid bars) and control clone NEO (gray bars)
injected at 105 cells per site in matrigel in the presence of an 0.18mg
estrogen implanted pellet. (B) BG-1 BRCA1 antisense clone AS-4
(solid bars) and control clone NEO (gray bars) injected at 105 cells per
site in matrigel without supplemental estrogen. The upper panels
indicate the percentage of injected sites that had tumor development.
The lower panels provide the average tumor size in millimeters (length
× width) for each clone on indicated days.regulated directly by hormones, the BRCA1 gene product
may be involved in the regulation of hormone response
pathways, and the present results may demonstrate that
loss of BRCA1 may result in loss of inhibitory control of
these mitogenic pathways.
BRCA1 transcription is regulated with the cell cycle, and
highest levels correlate with the G1/S-phase boundary
[5,9,41,47–49]. The present studies show that reduction
of BRCA1 mRNA and protein can result in increased pro-
liferation of BG-1 ovarian cancer cells in vitro and in vivo,
suggesting that BRCA1 may normally be acting as a
growth inhibitor. Similar to our findings with ovarian carci-
noma cells, accelerated growth, anchorage independence
and tumorigenicity is associated with BRCA1 antisense
introduction into mouse NIH3T3 cells [50]. In addition,
increased proliferation of mammary cells is induced with
antisense oligonucleotides to BRCA1 [51]. Conversely,
introduction of full-length BRCA1 by retrovirus-mediated
gene transfer inhibited growth of breast and ovarian
cancer cell lines in both in vitro and in vivo experiments
[51], and transfection of BRCA1 into colon cancer cells
inhibited new DNA synthesis by 50% in addition to inhibi-
tion of S-phase progression, possibly through direct trans-
activation of the cell cycle inhibitor p21WAF1/CIP1 [49].
In multicellular mammalian organisms, a balance between
cell proliferation and cell death is extremely important for
the maintenance of normal healthy tissues. This is espe-
cially important during early embryonic development as well
as in the development and function of adult tissues such as
the gonadal cells (ie ovarian and testes) [41,48]. For
example,  BRCA1  expression is critical during development,
as evidenced by the embryonic lethality in transgenic
knockout mice [29,30,52]. Alternatively, overexpression of
BRCA1 may activate apoptosis or cell death [14]. Human
prostate cells with an introduced wild-type BRCA1 cDNA
demonstrated a threefold to sixfold increase in chemosen-
sitivity, as well as an increased susceptibility to drug-
induced apoptosis [53]. We found that clones with even
moderately reduced levels of BRCA1 protein appeared to
be relatively resistant to death due to estrogen deprivation.
Previous studies in our laboratory showed that response of
parental BG-1 cells and antisense clones to gamma radia-
tion were consistent with a p53 wildtype phenotype, indi-
cating that loss of estrogen dependence is probably not
due to a p53 mutation (unpublished data). Shao et al [14]
demonstrated that BRCA1 transfected into mouse 3T3
fibroblasts resulted in increased programmed cell death. In
support of this hypothesis, it has been shown that p53 and
BRCA1  can form stable complexes, and can coactivate
p21  and  bax genes, which may lead to the activation of the
apoptosis pathway [15]. The present data, which show that
cells with a reduction in BRCA1 have a survival advantage
in conditions where control cells fail to thrive, also supports
this hypothesis.
Like  p53,  BRCA1  has also been implicated in DNA
damage and repair pathways [7,48,54]. According to this
model, cells without normal BRCA1 activity may accumu-
late genetic alterations as a result of failure to arrest and
repair DNA damage or self-destruct, thereby leading to
genomic instability and neoplastic progression. It may not
be coincidental that BRCA1-mutant breast cancers are
preferentially linked to a ‘specific’ histopathologic pattern
that includes a high S-phase fraction of cells, aneuploidy,
and hormone receptor-negative status [45]. In addition, it
has been demonstrated [20] that hormone-dependent
tumors such as breast and ovarian cancers have a
decreased ability to undergo apoptosis. Although muta-
tions in this gene are uncommon in sporadic breast and
ovarian tumors, BRCA1 expression levels and protein
levels have been found to be reduced in sporadic human
breast carcinomas [16–19]. Other mechanisms that
involve gene regulation may allow for decreased expres-
sion of BRCA1 in sporadic tumors. Hypermethylation has
been observed in some sporadic breast tumors in the pro-
moter region of BRCA1, which may account for
decreased  BRCA1 transcription [55]. Low BRCA1 levels
found in sporadic cancers may play an important role in
tumorigenesis. The present data suggest that diminished
levels of BRCA1 not only accelerate proliferation in the
BG-1 ovarian carcinoma cell line, but appear to alter
tumorigenesis. The exact mechanism may be unknown,
but decreased BRCA1 levels appear to affect the ability to
arrest growth or die in the absence of estrogenic growth-
inducing conditions. We propose that the loss or reduc-
tion of BRCA1 may predispose a cell population to
neoplastic transformation by altering the balance between
cell death and proliferation/survival, rendering it more sen-
sitive to secondary genetic changes.
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